对人类和小鼠中罕见的GPR146基因变异的研究

IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Boyan Zhang , Antoine Rimbert , Antoine Lainé , Nicolette Huijkman , Niels Kloosterhuis , Marieke Smit , Bart van de Sluis , Jan Albert Kuivenhoven , Umesh Tharehalli
{"title":"对人类和小鼠中罕见的GPR146基因变异的研究","authors":"Boyan Zhang ,&nbsp;Antoine Rimbert ,&nbsp;Antoine Lainé ,&nbsp;Nicolette Huijkman ,&nbsp;Niels Kloosterhuis ,&nbsp;Marieke Smit ,&nbsp;Bart van de Sluis ,&nbsp;Jan Albert Kuivenhoven ,&nbsp;Umesh Tharehalli","doi":"10.1016/j.atherosclerosis.2025.119137","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>G-protein coupled receptor 146 (<em>GPR146</em>)-deficient mice exhibit a moderate 21 % reduction in plasma cholesterol. This is associated with decreased phosphorylation of ERK1/2 and reduced SREBP2 activity in the liver, which leads to lower VLDL secretion. Insight into the role of <em>GPR146</em> in humans is however limited. We therefore set out to study rare genetic variants in <em>GPR146</em> to improve our understanding of this new player in lipid metabolism.</div></div><div><h3>Methods</h3><div>We used whole genome sequencing data from UK Biobank participants to search for rare coding variants in <em>GPR146</em>. We first carried out gene-based burden tests (using SAIGE-GENE-framework) and examined the association of individual variants with plasma cholesterol levels. One of the variants (P62L) was also studied using the Global Lipids Genetics Consortium (GLGC) data set and in a knock-in mouse model.</div></div><div><h3>Results</h3><div>We found that the combination of rare genetic variants identified in <em>GPR146</em> is significantly associated with plasma cholesterol levels. Three rare variants, i.e. P62L, I129I, and A175T were individually associated with reduced plasma cholesterol. In the GLGC cohort, the P62L variant was associated with reductions in both HDL and LDL cholesterol. Follow-up experiments show lower plasma cholesterol levels in <em>GPR146</em><sup>P61L</sup> male and female mice (−13 %, p &lt; 0.05 and −15 %, p &lt; 0.005, respectively) when compared to controls due to a reduction in HDL cholesterol. The <em>GPR146</em><sup>P61L</sup> mice did not exhibit a change in VLDL secretion. In line, the ERK1/2 signalling pathway and <em>Srebp2</em> mRNA expression in liver homogenates, and the secretion of apoB by primary hepatocytes of <em>GPR146</em><sup>P61L</sup> and wild-type mice were unchanged.</div></div><div><h3>Conclusions</h3><div>This study shows that rare <em>GPR146</em> gene variants are associated with lower plasma cholesterol levels in humans. One of these variants, P62L is associated with reductions of HDL cholesterol and LDL cholesterol in humans while the ortholog in mice confers a loss of <em>GPR146</em> function leading to only reduced HDL cholesterol. How <em>GPR146</em> affects HDL metabolism in humans and mice remains to be resolved.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"403 ","pages":"Article 119137"},"PeriodicalIF":4.9000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A study into rare GPR146 gene variants in humans and mice\",\"authors\":\"Boyan Zhang ,&nbsp;Antoine Rimbert ,&nbsp;Antoine Lainé ,&nbsp;Nicolette Huijkman ,&nbsp;Niels Kloosterhuis ,&nbsp;Marieke Smit ,&nbsp;Bart van de Sluis ,&nbsp;Jan Albert Kuivenhoven ,&nbsp;Umesh Tharehalli\",\"doi\":\"10.1016/j.atherosclerosis.2025.119137\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and aims</h3><div>G-protein coupled receptor 146 (<em>GPR146</em>)-deficient mice exhibit a moderate 21 % reduction in plasma cholesterol. This is associated with decreased phosphorylation of ERK1/2 and reduced SREBP2 activity in the liver, which leads to lower VLDL secretion. Insight into the role of <em>GPR146</em> in humans is however limited. We therefore set out to study rare genetic variants in <em>GPR146</em> to improve our understanding of this new player in lipid metabolism.</div></div><div><h3>Methods</h3><div>We used whole genome sequencing data from UK Biobank participants to search for rare coding variants in <em>GPR146</em>. We first carried out gene-based burden tests (using SAIGE-GENE-framework) and examined the association of individual variants with plasma cholesterol levels. One of the variants (P62L) was also studied using the Global Lipids Genetics Consortium (GLGC) data set and in a knock-in mouse model.</div></div><div><h3>Results</h3><div>We found that the combination of rare genetic variants identified in <em>GPR146</em> is significantly associated with plasma cholesterol levels. Three rare variants, i.e. P62L, I129I, and A175T were individually associated with reduced plasma cholesterol. In the GLGC cohort, the P62L variant was associated with reductions in both HDL and LDL cholesterol. Follow-up experiments show lower plasma cholesterol levels in <em>GPR146</em><sup>P61L</sup> male and female mice (−13 %, p &lt; 0.05 and −15 %, p &lt; 0.005, respectively) when compared to controls due to a reduction in HDL cholesterol. The <em>GPR146</em><sup>P61L</sup> mice did not exhibit a change in VLDL secretion. In line, the ERK1/2 signalling pathway and <em>Srebp2</em> mRNA expression in liver homogenates, and the secretion of apoB by primary hepatocytes of <em>GPR146</em><sup>P61L</sup> and wild-type mice were unchanged.</div></div><div><h3>Conclusions</h3><div>This study shows that rare <em>GPR146</em> gene variants are associated with lower plasma cholesterol levels in humans. One of these variants, P62L is associated with reductions of HDL cholesterol and LDL cholesterol in humans while the ortholog in mice confers a loss of <em>GPR146</em> function leading to only reduced HDL cholesterol. How <em>GPR146</em> affects HDL metabolism in humans and mice remains to be resolved.</div></div>\",\"PeriodicalId\":8623,\"journal\":{\"name\":\"Atherosclerosis\",\"volume\":\"403 \",\"pages\":\"Article 119137\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-02-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atherosclerosis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0021915025000346\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0021915025000346","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景和靶蛋白偶联受体146 (GPR146)缺陷小鼠血浆胆固醇适度降低21%。这与肝脏中ERK1/2磷酸化降低和SREBP2活性降低有关,从而导致VLDL分泌降低。然而,对GPR146在人类中的作用的了解有限。因此,我们开始研究GPR146的罕见遗传变异,以提高我们对这种脂质代谢新参与者的理解。方法利用英国生物银行(UK Biobank)参与者的全基因组测序数据,寻找GPR146中罕见的编码变异。我们首先进行了基于基因的负荷测试(使用SAIGE-GENE-framework),并检查了个体变异与血浆胆固醇水平的关系。其中一种变体(P62L)也使用全球脂质遗传学联盟(GLGC)数据集和敲入小鼠模型进行了研究。结果我们发现在GPR146中鉴定的罕见遗传变异组合与血浆胆固醇水平显著相关。P62L、I129I和A175T这三种罕见的变异分别与血浆胆固醇降低有关。在GLGC队列中,P62L变异与HDL和LDL胆固醇的降低有关。后续实验表明,GPR146P61L雄性和雌性小鼠血浆胆固醇水平较低(- 13%,p <;0.05和- 15%,p <;(分别为0.005),这是由于高密度脂蛋白胆固醇的降低。GPR146P61L小鼠的VLDL分泌没有变化。与此同时,肝脏匀浆中ERK1/2信号通路和Srebp2 mRNA的表达以及GPR146P61L和野生型小鼠原代肝细胞分泌apoB的情况均未发生变化。结论本研究表明罕见的GPR146基因变异与人类较低的血浆胆固醇水平有关。其中一种变体P62L与人类高密度脂蛋白胆固醇和低密度脂蛋白胆固醇的降低有关,而小鼠的同源基因GPR146功能的丧失只导致高密度脂蛋白胆固醇的降低。GPR146如何影响人类和小鼠的高密度脂蛋白代谢仍有待解决。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A study into rare GPR146 gene variants in humans and mice

A study into rare GPR146 gene variants in humans and mice

Background and aims

G-protein coupled receptor 146 (GPR146)-deficient mice exhibit a moderate 21 % reduction in plasma cholesterol. This is associated with decreased phosphorylation of ERK1/2 and reduced SREBP2 activity in the liver, which leads to lower VLDL secretion. Insight into the role of GPR146 in humans is however limited. We therefore set out to study rare genetic variants in GPR146 to improve our understanding of this new player in lipid metabolism.

Methods

We used whole genome sequencing data from UK Biobank participants to search for rare coding variants in GPR146. We first carried out gene-based burden tests (using SAIGE-GENE-framework) and examined the association of individual variants with plasma cholesterol levels. One of the variants (P62L) was also studied using the Global Lipids Genetics Consortium (GLGC) data set and in a knock-in mouse model.

Results

We found that the combination of rare genetic variants identified in GPR146 is significantly associated with plasma cholesterol levels. Three rare variants, i.e. P62L, I129I, and A175T were individually associated with reduced plasma cholesterol. In the GLGC cohort, the P62L variant was associated with reductions in both HDL and LDL cholesterol. Follow-up experiments show lower plasma cholesterol levels in GPR146P61L male and female mice (−13 %, p < 0.05 and −15 %, p < 0.005, respectively) when compared to controls due to a reduction in HDL cholesterol. The GPR146P61L mice did not exhibit a change in VLDL secretion. In line, the ERK1/2 signalling pathway and Srebp2 mRNA expression in liver homogenates, and the secretion of apoB by primary hepatocytes of GPR146P61L and wild-type mice were unchanged.

Conclusions

This study shows that rare GPR146 gene variants are associated with lower plasma cholesterol levels in humans. One of these variants, P62L is associated with reductions of HDL cholesterol and LDL cholesterol in humans while the ortholog in mice confers a loss of GPR146 function leading to only reduced HDL cholesterol. How GPR146 affects HDL metabolism in humans and mice remains to be resolved.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Atherosclerosis
Atherosclerosis 医学-外周血管病
CiteScore
9.80
自引率
3.80%
发文量
1269
审稿时长
36 days
期刊介绍: Atherosclerosis has an open access mirror journal Atherosclerosis: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations. Atherosclerosis covers basic and translational, clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, thrombosis, and inflammation. The Editors are interested in original or review papers dealing with the pathogenesis, environmental, genetic and epigenetic basis, diagnosis or treatment of atherosclerosis and related diseases as well as their risk factors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信